Apellis Pharmaceuticals Inc

Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

The first full business week of the new year began with plenty of clinical trial news. Here’s a look.

Apellis Pharmaceuticals announced that its pegcetacoplan beat out Alexion Pharmaceuticals’ Soliris in its Phase III PEGASUS study in adults with paroxysmal nocturnal hemoglobinuria.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that the company will participate in the following upcoming investor conferences in December

Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.

Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.

The JP Morgan Healthcare Conference is wrapping up today and as usual, it’s host to some of the biggest names in biopharma, but it’s also a venue where tiny biotechs and even mid-size biopharma companies go to meet-and-greet with others in the industry.

The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15.